Varicose Veins Treatment Industry - Regional Synopsis
North America Market Analysis
The North America region in the varicose veins treatment market is projected to hold the largest share of 43.8% by the end of 2037. This regional growth is fueled by the presence of both Medicaid and Medicare coverage policies, as well as innovative minimally invasive treatment procedures. The U.S. is projected to account for 89.5% of the overall domestic revenue, with 6.8 million yearly procedures by 2037. On the other hand, Canada’s growth is subjected to expansion in provincial healthcare, with Ontario covering 85.6% of sclerotherapy costs. Therefore, all these factors are highly responsible for driving the market in the region.
The market in the U.S. is undergoing accelerated upliftment due to factors such as increasing insurance coverage and regulatory acceptance of cutting-edge devices. For instance, the U.S. FDA approved 14 latest varicose vein treatment devices in 2024, which included three artificial-intelligence-based diagnostic tools. Besides, in 2025, Medicare’s Physician Fee Schedule enhanced the reimbursement policy by 8.5% for endovenous ablation, which is poised to surge by 23.6% in terms of ASC-based procedures, thereby providing a suitable upliftment for the market in the country.
The varicose veins treatment market in Canada is gaining increased traction owing to cost-effectiveness for outpatient care based on single-payer system, comprising 7 provinces that cover ultrasound-guided sclerotherapy. According to the 2024 BC MOH report, British Columbia’s 2024 Surgical Renewal Plan provided a fund of USD 190 million to keep a check on the varicose vein treatment waitlists, which further reduced average delays from 20 to 10 months. Besides, device procurement remains a barrier, wherein 29% of hospitals report over seven months delay, especially for imported laser fibers, which ultimately prompts the latest federal tax credits for regional medtech manufacturing facilities.
Europe Regional Market Size & Growth
The Europe region in the varicose veins treatment market is projected to account for the second-highest share of 28.9% during the forecast timeline. This growth is highly driven by the rising aging population and the presence of universal healthcare and medical coverage policies. The country has regulatory bodies to approve the latest devices for undergoing treatment procedures. For instance, in 2024, the EU Medical Device Regulation (MDR) enhanced the adoption of non-thermal ablation devices, which currently covers almost 75.5% of overall treatment and diagnostic procedures, thus suitable for uplifting the market in the region.
The varicose veins treatment market in Germany is significantly growing, attributed to the availability of a compulsory health insurance system covering almost 92.5% of minimally invasive procedures. However, stringent price control caps the reimbursement policy at €1,200.5 per procedure, which eventually squeezes margins up to 11% to 16% for device manufacturers. Besides, the regional production facility is responsible for combating costs with 46% of laser devices manufactured by local organizations such as Biolitec AG, thereby amplifying the market expansion in the country.
The market growth in France is propelled by the presence of HAS policies that are considered mandatory for 81% of procedures, especially in an outpatient environment. Moreover, the regional government allocated an investment of €1.2 billion, which is 7.4% of the overall health budget, to ensure varicose veins treatment in 2025. This resulted in prioritizing similar day discharge protocols that diminished hospital accommodation by 30.8%. In addition, tele-rehabilitation programs reduced re-admissions by almost 18.7%, which also contributed to the market expansion in the country.
